Pure Global

An Observational Study to Learn About the Occurrence of Disseminated Intravascular Coagulation Among Adults With Sepsis in Japan - Trial NCT06373159

Access comprehensive clinical trial information for NCT06373159 through Pure Global AI's free database. This phase not specified trial is sponsored by Bayer and is currently Recruitment Completed. The study focuses on Sepsis,Disseminated Intravascular Coagulation. Target enrollment is 5740 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06373159
Recruitment Completed
other
Trial Details
ClinicalTrials.gov โ€ข NCT06373159
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
An Observational Study to Learn About the Occurrence of Disseminated Intravascular Coagulation Among Adults With Sepsis in Japan
A Study for the Disseminated Intravascular Coagulation Among Patients With Sepsis in Japan: A Hospital-based Cohort Study

Study Focus

No study intervention

Observational

other

Sponsor & Location

Bayer

Tokyo, Japan

Timeline & Enrollment

N/A

Apr 10, 2024

Sep 30, 2024

5740 participants

Primary Outcome

Incidence of DIC assessed at 14 days, 21 days and 28 days of the patient follow up,Distribution of JAAM DIC score,Distribution of ISTH DIC score,Distribution of MHLW DIC score,Distribution of SOFA score,Days from sepsis diagnosis to the onset of DIC

Summary

This is an observational study in which data already collected from people with sepsis (blood
 poisoning) and/or disseminated intravascular coagulation (DIC) are studied.
 
 In observational studies, only observations are made without participants receiving any
 advice or changes to their healthcare.
 
 DIC is a serious blood disorder that can cause clots throughout the body, blocking blood
 vessels. People who have sepsis or cancer are at a higher risk of developing DIC.
 
 To find a treatment that works well for people with DIC associated with sepsis, it is
 important to know about its occurrence, treatments people receive, and their outcomes. Japan
 is the only country that has officially approved medicines for DIC including a few newer
 medicines that prevent extensive blood clotting.
 
 In this study, researchers will assess patient data from a hospital database in Japan.
 
 The main purpose of this study is to learn more about how many adults develop DIC related to
 sepsis, thrombocytopenic sepsis (sudden decrease in the number of platelets in the blood), or
 septic shock (dangerously low blood pressure) in Japan every year.
 
 To learn about this, researchers will collect the following information:
 
 - The number of participants who developed DIC 14 days, 21 days and 28 days after their
 sepsis diagnosis
 
 - The grading scores given to the participants which are used to assess the likelihood,
 cause, severity, treatment plan, and outcome of DIC (including scores called JAAM, ISTH,
 MHLW, and/or SOFA scores)
 
 - The number of days between diagnosis of sepsis and the beginning of DIC
 
 Researchers will study the data collected between June 2018 and June 2023. The data will come
 from TXP Medical, which collects data through the hospital health information system of 7
 selected hospitals for this study across Japan.
 
 In this study, only available data from routine care are collected.

ICD-10 Classifications

Disseminated intravascular coagulation of fetus and newborn
Disseminated intravascular coagulation [defibrination syndrome]
Sepsis, unspecified
Other specified sepsis
Other sepsis

Data Source

ClinicalTrials.gov

NCT06373159

Non-Device Trial